APO Research
Talk to an analyst

APO RESEARCH · REPORT

Herpes Zoste Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Herpes Zoste Drug Market Outlook and Growth Opportunities 2026

26 December 2025192 pages

Choose your research edition.

Industry ResearchHerpes Zoste Drug Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal Herpes Zoste Drug Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Herpes Zoste Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Herpes Zoste Drug Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Herpes Zoste Drug Market Analysis and Forecast 2026-2032212 pages · $4,950 USD

Market perspective

The global Herpes Zoste Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Herpes Zoste Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Herpes Zoste Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Herpes Zoste Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Herpes Zoste Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Herpes Zoste Drug market include Merck & Co., Inc., Beijing Minhai Biotechnology Co., Ltd, Astellas Pharma Inc., TSRL, Inc., ReceptoPharm, Inc., NAL Pharmaceuticals Ltd., GlaxoSmithKline Plc, GeneOne Life Science, Inc. and Foamix Pharmaceuticals Ltd., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Herpes Zoste Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Herpes Zoste Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Herpes Zoste Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Herpes Zoste Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Herpes Zoste Drug Segment by Company

Merck & Co., Inc.

Beijing Minhai Biotechnology Co., Ltd

Astellas Pharma Inc.

TSRL, Inc.

ReceptoPharm, Inc.

NAL Pharmaceuticals Ltd.

GlaxoSmithKline Plc

GeneOne Life Science, Inc.

Foamix Pharmaceuticals Ltd.

Epiphany Biosciences, Inc.

ContraVir Pharmaceuticals, Inc.

Herpes Zoste Drug Segment by Type

FV-100

GLS-5100

GSK-1437173A

NAL-3221

Amenamevir

Acyclovir

Others

Herpes Zoste Drug Segment by Application

Clinic

Hospital

Others

Herpes Zoste Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Herpes Zoste Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Herpes Zoste Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Herpes Zoste Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Herpes Zoste Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Herpes Zoste Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Herpes Zoste Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Herpes Zoste Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Herpes Zoste Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Herpes Zoste Drug industry.

Chapter 3: Detailed analysis of Herpes Zoste Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Herpes Zoste Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Herpes Zoste Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Herpes Zoste Drug Industry Trends Table 2. Herpes Zoste Drug Industry Drivers Table 3. Herpes Zoste Drug Industry Opportunities and Challenges Table 4. Herpes Zoste Drug Industry Restraints Table 5. Global Herpes Zoste Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Herpes Zoste Drug Revenue Share by Company (2021-2026) Table 7. Global Herpes Zoste Drug Sales Volume by Company (W Units) & (2021-2026) Table 8. Global Herpes Zoste Drug Sales Volume Share by Company (2021-2026) Table 9. Global Herpes Zoste Drug Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Herpes Zoste Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Herpes Zoste Drug Key Company Manufacturing Base & Headquarters Table 12. Global Herpes Zoste Drug Company, Product Type & Application Table 13. Global Herpes Zoste Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Herpes Zoste Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of FV-100 Table 18. Significant Companies of GLS-5100 Table 19. Significant Companies of GSK-1437173A Table 20. Significant Companies of NAL-3221 Table 21. Significant Companies of Amenamevir Table 22. Significant Companies of Acyclovir Table 23. Significant Companies of Others Table 24. Global Herpes Zoste Drug Sales Volume by Type 2021 VS 2025 VS 2032 (W Units) Table 25. Global Herpes Zoste Drug Sales Volume by Type (2021-2026) & (W Units) Table 26. Global Herpes Zoste Drug Sales Volume by Type (2027-2032) & (W Units) Table 27. Global Herpes Zoste Drug Sales Volume Share by Type (2021-2026) Table 28. Global Herpes Zoste Drug Sales Volume Share by Type (2027-2032) Table 29. Global Herpes Zoste Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Herpes Zoste Drug Sales Value by Type (2021-2026) & (US$ Million) Table 31. Global Herpes Zoste Drug Sales Value by Type (2027-2032) & (US$ Million) Table 32. Global Herpes Zoste Drug Sales Value Share by Type (2021-2026) Table 33. Global Herpes Zoste Drug Sales Value Share by Type (2027-2032) Table 34. Significant Companies of Clinic Table 35. Significant Companies of Hospital Table 36. Significant Companies of Others Table 37. Global Herpes Zoste Drug Sales Volume by Application 2021 VS 2025 VS 2032 (W Units) Table 38. Global Herpes Zoste Drug Sales Volume by Application (2021-2026) & (W Units) Table 39. Global Herpes Zoste Drug Sales Volume by Application (2027-2032) & (W Units) Table 40. Global Herpes Zoste Drug Sales Volume Share by Application (2021-2026) Table 41. Global Herpes Zoste Drug Sales Volume Share by Application (2027-2032) Table 42. Global Herpes Zoste Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 43. Global Herpes Zoste Drug Sales Value by Application (2021-2026) & (US$ Million) Table 44. Global Herpes Zoste Drug Sales Value by Application (2027-2032) & (US$ Million) Table 45. Global Herpes Zoste Drug Sales Value Share by Application (2021-2026) Table 46. Global Herpes Zoste Drug Sales Value Share by Application (2027-2032) Table 47. Global Herpes Zoste Drug Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 48. Global Herpes Zoste Drug Sales by Region (2021-2026) & (W Units) Table 49. Global Herpes Zoste Drug Sales Market Share by Region (2021-2026) Table 50. Global Herpes Zoste Drug Sales by Region (2027-2032) & (W Units) Table 51. Global Herpes Zoste Drug Sales Market Share by Region (2027-2032) Table 52. Global Herpes Zoste Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 53. Global Herpes Zoste Drug Sales Value by Region (2021-2026) & (US$ Million) Table 54. Global Herpes Zoste Drug Sales Value Share by Region (2021-2026) Table 55. Global Herpes Zoste Drug Sales Value by Region (2027-2032) & (US$ Million) Table 56. Global Herpes Zoste Drug Sales Value Share by Region (2027-2032) Table 57. Global Herpes Zoste Drug Market Average Price (US$/Unit) by Region (2021-2026) Table 58. Global Herpes Zoste Drug Market Average Price (US$/Unit) by Region (2027-2032) Table 59. Global Herpes Zoste Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Table 60. Global Herpes Zoste Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Herpes Zoste Drug Sales by Country (2021-2026) & (W Units) Table 62. Global Herpes Zoste Drug Sales Market Share by Country (2021-2026) Table 63. Global Herpes Zoste Drug Sales by Country (2027-2032) & (W Units) Table 64. Global Herpes Zoste Drug Sales Market Share by Country (2027-2032) Table 65. Global Herpes Zoste Drug Sales Value by Country (2021-2026) & (US$ Million) Table 66. Global Herpes Zoste Drug Sales Value Market Share by Country (2021-2026) Table 67. Global Herpes Zoste Drug Sales Value by Country (2027-2032) & (US$ Million) Table 68. Global Herpes Zoste Drug Sales Value Market Share by Country (2027-2032) Table 69. Merck & Co., Inc. Company Information Table 70. Merck & Co., Inc. Business Overview Table 71. Merck & Co., Inc. Herpes Zoste Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Merck & Co., Inc. Herpes Zoste Drug Product Portfolio Table 73. Merck & Co., Inc. Recent Development Table 74. Beijing Minhai Biotechnology Co., Ltd Company Information Table 75. Beijing Minhai Biotechnology Co., Ltd Business Overview Table 76. Beijing Minhai Biotechnology Co., Ltd Herpes Zoste Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Beijing Minhai Biotechnology Co., Ltd Herpes Zoste Drug Product Portfolio Table 78. Beijing Minhai Biotechnology Co., Ltd Recent Development Table 79. Astellas Pharma Inc. Company Information Table 80. Astellas Pharma Inc. Business Overview Table 81. Astellas Pharma Inc. Herpes Zoste Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Astellas Pharma Inc. Herpes Zoste Drug Product Portfolio Table 83. Astellas Pharma Inc. Recent Development Table 84. TSRL, Inc. Company Information Table 85. TSRL, Inc. Business Overview Table 86. TSRL, Inc. Herpes Zoste Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. TSRL, Inc. Herpes Zoste Drug Product Portfolio Table 88. TSRL, Inc. Recent Development Table 89. ReceptoPharm, Inc. Company Information Table 90. ReceptoPharm, Inc. Business Overview Table 91. ReceptoPharm, Inc. Herpes Zoste Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. ReceptoPharm, Inc. Herpes Zoste Drug Product Portfolio Table 93. ReceptoPharm, Inc. Recent Development Table 94. NAL Pharmaceuticals Ltd. Company Information Table 95. NAL Pharmaceuticals Ltd. Business Overview Table 96. NAL Pharmaceuticals Ltd. Herpes Zoste Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. NAL Pharmaceuticals Ltd. Herpes Zoste Drug Product Portfolio Table 98. NAL Pharmaceuticals Ltd. Recent Development Table 99. GlaxoSmithKline Plc Company Information Table 100. GlaxoSmithKline Plc Business Overview Table 101. GlaxoSmithKline Plc Herpes Zoste Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. GlaxoSmithKline Plc Herpes Zoste Drug Product Portfolio Table 103. GlaxoSmithKline Plc Recent Development Table 104. GeneOne Life Science, Inc. Company Information Table 105. GeneOne Life Science, Inc. Business Overview Table 106. GeneOne Life Science, Inc. Herpes Zoste Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. GeneOne Life Science, Inc. Herpes Zoste Drug Product Portfolio Table 108. GeneOne Life Science, Inc. Recent Development Table 109. Foamix Pharmaceuticals Ltd. Company Information Table 110. Foamix Pharmaceuticals Ltd. Business Overview Table 111. Foamix Pharmaceuticals Ltd. Herpes Zoste Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Foamix Pharmaceuticals Ltd. Herpes Zoste Drug Product Portfolio Table 113. Foamix Pharmaceuticals Ltd. Recent Development Table 114. Epiphany Biosciences, Inc. Company Information Table 115. Epiphany Biosciences, Inc. Business Overview Table 116. Epiphany Biosciences, Inc. Herpes Zoste Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Epiphany Biosciences, Inc. Herpes Zoste Drug Product Portfolio Table 118. Epiphany Biosciences, Inc. Recent Development Table 119. ContraVir Pharmaceuticals, Inc. Company Information Table 120. ContraVir Pharmaceuticals, Inc. Business Overview Table 121. ContraVir Pharmaceuticals, Inc. Herpes Zoste Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. ContraVir Pharmaceuticals, Inc. Herpes Zoste Drug Product Portfolio Table 123. ContraVir Pharmaceuticals, Inc. Recent Development Table 124. Key Raw Materials Table 125. Raw Materials Key Suppliers Table 126. Herpes Zoste Drug Distributors List Table 127. Herpes Zoste Drug Customers List Table 128. Research Programs/Design for This Report Table 129. Authors List of This Report Table 130. Secondary Sources Table 131. Primary Sources List of Figures Figure 1. Herpes Zoste Drug Product Image Figure 2. Global Herpes Zoste Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Herpes Zoste Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Herpes Zoste Drug Sales (2021-2032) & (W Units) Figure 5. Global Herpes Zoste Drug Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Herpes Zoste Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. FV-100 Image Figure 10. GLS-5100 Image Figure 11. GSK-1437173A Image Figure 12. NAL-3221 Image Figure 13. Amenamevir Image Figure 14. Acyclovir Image Figure 15. Others Image Figure 16. Global Herpes Zoste Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (W Units) Figure 17. Global Herpes Zoste Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 18. Global Herpes Zoste Drug Sales Volume Share by Type (2021-2032) Figure 19. Global Herpes Zoste Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Herpes Zoste Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 21. Global Herpes Zoste Drug Sales Value Share by Type (2021-2032) Figure 22. Clinic Image Figure 23. Hospital Image Figure 24. Others Image Figure 25. Global Herpes Zoste Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (W Units) Figure 26. Global Herpes Zoste Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 27. Global Herpes Zoste Drug Sales Volume Share by Application (2021-2032) Figure 28. Global Herpes Zoste Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 29. Global Herpes Zoste Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 30. Global Herpes Zoste Drug Sales Value Share by Application (2021-2032) Figure 31. Global Herpes Zoste Drug Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 32. Global Herpes Zoste Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 33. Global Herpes Zoste Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 34. Global Herpes Zoste Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 35. North America Herpes Zoste Drug Sales Value (2021-2032) & (US$ Million) Figure 36. North America Herpes Zoste Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Europe Herpes Zoste Drug Sales Value (2021-2032) & (US$ Million) Figure 38. Europe Herpes Zoste Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Asia-Pacific Herpes Zoste Drug Sales Value (2021-2032) & (US$ Million) Figure 40. Asia-Pacific Herpes Zoste Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 41. South America Herpes Zoste Drug Sales Value (2021-2032) & (US$ Million) Figure 42. South America Herpes Zoste Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 43. Middle East & Africa Herpes Zoste Drug Sales Value (2021-2032) & (US$ Million) Figure 44. Middle East & Africa Herpes Zoste Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 45. USA Herpes Zoste Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. USA Herpes Zoste Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. USA Herpes Zoste Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Canada Herpes Zoste Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Canada Herpes Zoste Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Canada Herpes Zoste Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Mexico Herpes Zoste Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Mexico Herpes Zoste Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Mexico Herpes Zoste Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Germany Herpes Zoste Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Germany Herpes Zoste Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Germany Herpes Zoste Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. France Herpes Zoste Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. France Herpes Zoste Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. France Herpes Zoste Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. U.K. Herpes Zoste Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. U.K. Herpes Zoste Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. U.K. Herpes Zoste Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Italy Herpes Zoste Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Italy Herpes Zoste Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Italy Herpes Zoste Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Spain Herpes Zoste Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Spain Herpes Zoste Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Spain Herpes Zoste Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Russia Herpes Zoste Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Russia Herpes Zoste Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Russia Herpes Zoste Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Netherlands Herpes Zoste Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Netherlands Herpes Zoste Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Netherlands Herpes Zoste Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Nordic Countries Herpes Zoste Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Nordic Countries Herpes Zoste Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Nordic Countries Herpes Zoste Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. China Herpes Zoste Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. China Herpes Zoste Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. China Herpes Zoste Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Japan Herpes Zoste Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Japan Herpes Zoste Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Japan Herpes Zoste Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. South Korea Herpes Zoste Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. South Korea Herpes Zoste Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. South Korea Herpes Zoste Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. India Herpes Zoste Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. India Herpes Zoste Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. India Herpes Zoste Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Australia Herpes Zoste Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Australia Herpes Zoste Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Australia Herpes Zoste Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Southeast Asia Herpes Zoste Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Southeast Asia Herpes Zoste Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Southeast Asia Herpes Zoste Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Brazil Herpes Zoste Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Brazil Herpes Zoste Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Brazil Herpes Zoste Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Argentina Herpes Zoste Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Argentina Herpes Zoste Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Argentina Herpes Zoste Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Chile Herpes Zoste Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Chile Herpes Zoste Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Chile Herpes Zoste Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Colombia Herpes Zoste Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Colombia Herpes Zoste Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Colombia Herpes Zoste Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Peru Herpes Zoste Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Peru Herpes Zoste Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Peru Herpes Zoste Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Herpes Zoste Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Saudi Arabia Herpes Zoste Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Saudi Arabia Herpes Zoste Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Israel Herpes Zoste Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Israel Arabia Herpes Zoste Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Israel Arabia Herpes Zoste Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. UAE Herpes Zoste Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. UAE Herpes Zoste Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. UAE Herpes Zoste Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Turkey Herpes Zoste Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Turkey Herpes Zoste Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Turkey Herpes Zoste Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Iran Herpes Zoste Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Iran Herpes Zoste Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Iran Herpes Zoste Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Egypt Herpes Zoste Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 127. Egypt Herpes Zoste Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 128. Egypt Herpes Zoste Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 129. Herpes Zoste Drug Value Chain Figure 130. Manufacturing Cost Structure Figure 131. Herpes Zoste Drug Sales Mode & Process Figure 132. Direct Comparison with Distribution Share Figure 133. Distributors Profiles Figure 134. Years Considered Figure 135. Research Process Figure 136. Key Executives Interviewed

Scope & coverage.

Types
  • FV-100
  • GLS-5100
  • GSK-1437173A
  • NAL-3221
  • Amenamevir
  • Acyclovir
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • Merck & Co., Inc.
  • Beijing Minhai Biotechnology Co., Ltd
  • Astellas Pharma Inc.
  • TSRL, Inc.
  • ReceptoPharm, Inc.
  • NAL Pharmaceuticals Ltd.
  • GlaxoSmithKline Plc
  • GeneOne Life Science, Inc.
  • Foamix Pharmaceuticals Ltd.
  • Epiphany Biosciences, Inc.
  • ContraVir Pharmaceuticals, Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Herpes Zoste Drug Sales Value (2021-2032)
  4. 1.2.2 Global Herpes Zoste Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Herpes Zoste Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Herpes Zoste Drug Market Dynamics
  1. 2.1 Herpes Zoste Drug Industry Trends
  2. 2.2 Herpes Zoste Drug Industry Drivers
  3. 2.3 Herpes Zoste Drug Industry Opportunities and Challenges
  4. 2.4 Herpes Zoste Drug Industry Restraints
3 Herpes Zoste Drug Market by Company
  1. 3.1 Global Herpes Zoste Drug Company Revenue Ranking in 2025
  2. 3.2 Global Herpes Zoste Drug Revenue by Company (2021-2026)
  3. 3.3 Global Herpes Zoste Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Herpes Zoste Drug Average Price by Company (2021-2026)
  5. 3.5 Global Herpes Zoste Drug Company Ranking (2024-2026)
  6. 3.6 Global Herpes Zoste Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Herpes Zoste Drug Company Product Type and Application
  8. 3.8 Global Herpes Zoste Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Herpes Zoste Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Herpes Zoste Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Herpes Zoste Drug Market by Type
  1. 4.1 Herpes Zoste Drug Type Introduction
  2. 4.1.1 FV-100
  3. 4.1.2 GLS-5100
  4. 4.1.3 GSK-1437173A
  5. 4.1.4 NAL-3221
  6. 4.1.5 Amenamevir
  7. 4.1.6 Acyclovir
  8. 4.1.7 Others
  9. 4.2 Global Herpes Zoste Drug Sales Volume by Type
  10. 4.2.1 Global Herpes Zoste Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  11. 4.2.2 Global Herpes Zoste Drug Sales Volume by Type (2021-2032)
  12. 4.2.3 Global Herpes Zoste Drug Sales Volume Share by Type (2021-2032)
  13. 4.3 Global Herpes Zoste Drug Sales Value by Type
  14. 4.3.1 Global Herpes Zoste Drug Sales Value by Type (2021 VS 2025 VS 2032)
  15. 4.3.2 Global Herpes Zoste Drug Sales Value by Type (2021-2032)
  16. 4.3.3 Global Herpes Zoste Drug Sales Value Share by Type (2021-2032)
5 Herpes Zoste Drug Market by Application
  1. 5.1 Herpes Zoste Drug Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Others
  5. 5.2 Global Herpes Zoste Drug Sales Volume by Application
  6. 5.2.1 Global Herpes Zoste Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Herpes Zoste Drug Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Herpes Zoste Drug Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Herpes Zoste Drug Sales Value by Application
  10. 5.3.1 Global Herpes Zoste Drug Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Herpes Zoste Drug Sales Value by Application (2021-2032)
  12. 5.3.3 Global Herpes Zoste Drug Sales Value Share by Application (2021-2032)
6 Herpes Zoste Drug Regional Sales and Value Analysis
  1. 6.1 Global Herpes Zoste Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Herpes Zoste Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Herpes Zoste Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Herpes Zoste Drug Sales by Region (2027-2032)
  5. 6.3 Global Herpes Zoste Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Herpes Zoste Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Herpes Zoste Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Herpes Zoste Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Herpes Zoste Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Herpes Zoste Drug Sales Value (2021-2032)
  12. 6.6.2 North America Herpes Zoste Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Herpes Zoste Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Herpes Zoste Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Herpes Zoste Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Herpes Zoste Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Herpes Zoste Drug Sales Value (2021-2032)
  21. 6.9.2 South America Herpes Zoste Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Herpes Zoste Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Herpes Zoste Drug Sales Value Share by Country, 2025 VS 2032
7 Herpes Zoste Drug Country-level Sales and Value Analysis
  1. 7.1 Global Herpes Zoste Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Herpes Zoste Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Herpes Zoste Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Herpes Zoste Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Herpes Zoste Drug Sales by Country (2027-2032)
  6. 7.4 Global Herpes Zoste Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Herpes Zoste Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Herpes Zoste Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Herpes Zoste Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Herpes Zoste Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Herpes Zoste Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Herpes Zoste Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Herpes Zoste Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Herpes Zoste Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Herpes Zoste Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Herpes Zoste Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Herpes Zoste Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Herpes Zoste Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Herpes Zoste Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Herpes Zoste Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Herpes Zoste Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Herpes Zoste Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Herpes Zoste Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Herpes Zoste Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Herpes Zoste Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Herpes Zoste Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Herpes Zoste Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Herpes Zoste Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Herpes Zoste Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Herpes Zoste Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Herpes Zoste Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Herpes Zoste Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Herpes Zoste Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Herpes Zoste Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Herpes Zoste Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Herpes Zoste Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Herpes Zoste Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Herpes Zoste Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Herpes Zoste Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Herpes Zoste Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Herpes Zoste Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Herpes Zoste Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Herpes Zoste Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Herpes Zoste Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Herpes Zoste Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Herpes Zoste Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Herpes Zoste Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Herpes Zoste Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Herpes Zoste Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Herpes Zoste Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Herpes Zoste Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Herpes Zoste Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Herpes Zoste Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Herpes Zoste Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Herpes Zoste Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Herpes Zoste Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Herpes Zoste Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Herpes Zoste Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Herpes Zoste Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Herpes Zoste Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Herpes Zoste Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Herpes Zoste Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Herpes Zoste Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Herpes Zoste Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Herpes Zoste Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Herpes Zoste Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Herpes Zoste Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Herpes Zoste Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Herpes Zoste Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Herpes Zoste Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Herpes Zoste Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Herpes Zoste Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Herpes Zoste Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Herpes Zoste Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Herpes Zoste Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Herpes Zoste Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Herpes Zoste Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Herpes Zoste Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Herpes Zoste Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Herpes Zoste Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Herpes Zoste Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Herpes Zoste Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Herpes Zoste Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Herpes Zoste Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Herpes Zoste Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Herpes Zoste Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Herpes Zoste Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Herpes Zoste Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Herpes Zoste Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Herpes Zoste Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Herpes Zoste Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Herpes Zoste Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Merck & Co., Inc.
  2. 8.1.1 Merck & Co., Inc. Company Information
  3. 8.1.2 Merck & Co., Inc. Business Overview
  4. 8.1.3 Merck & Co., Inc. Herpes Zoste Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Merck & Co., Inc. Herpes Zoste Drug Product Portfolio
  6. 8.1.5 Merck & Co., Inc. Recent Developments
  7. 8.2 Beijing Minhai Biotechnology Co., Ltd
  8. 8.2.1 Beijing Minhai Biotechnology Co., Ltd Company Information
  9. 8.2.2 Beijing Minhai Biotechnology Co., Ltd Business Overview
  10. 8.2.3 Beijing Minhai Biotechnology Co., Ltd Herpes Zoste Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Beijing Minhai Biotechnology Co., Ltd Herpes Zoste Drug Product Portfolio
  12. 8.2.5 Beijing Minhai Biotechnology Co., Ltd Recent Developments
  13. 8.3 Astellas Pharma Inc.
  14. 8.3.1 Astellas Pharma Inc. Company Information
  15. 8.3.2 Astellas Pharma Inc. Business Overview
  16. 8.3.3 Astellas Pharma Inc. Herpes Zoste Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Astellas Pharma Inc. Herpes Zoste Drug Product Portfolio
  18. 8.3.5 Astellas Pharma Inc. Recent Developments
  19. 8.4 TSRL, Inc.
  20. 8.4.1 TSRL, Inc. Company Information
  21. 8.4.2 TSRL, Inc. Business Overview
  22. 8.4.3 TSRL, Inc. Herpes Zoste Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 TSRL, Inc. Herpes Zoste Drug Product Portfolio
  24. 8.4.5 TSRL, Inc. Recent Developments
  25. 8.5 ReceptoPharm, Inc.
  26. 8.5.1 ReceptoPharm, Inc. Company Information
  27. 8.5.2 ReceptoPharm, Inc. Business Overview
  28. 8.5.3 ReceptoPharm, Inc. Herpes Zoste Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 ReceptoPharm, Inc. Herpes Zoste Drug Product Portfolio
  30. 8.5.5 ReceptoPharm, Inc. Recent Developments
  31. 8.6 NAL Pharmaceuticals Ltd.
  32. 8.6.1 NAL Pharmaceuticals Ltd. Company Information
  33. 8.6.2 NAL Pharmaceuticals Ltd. Business Overview
  34. 8.6.3 NAL Pharmaceuticals Ltd. Herpes Zoste Drug Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 NAL Pharmaceuticals Ltd. Herpes Zoste Drug Product Portfolio
  36. 8.6.5 NAL Pharmaceuticals Ltd. Recent Developments
  37. 8.7 GlaxoSmithKline Plc
  38. 8.7.1 GlaxoSmithKline Plc Company Information
  39. 8.7.2 GlaxoSmithKline Plc Business Overview
  40. 8.7.3 GlaxoSmithKline Plc Herpes Zoste Drug Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 GlaxoSmithKline Plc Herpes Zoste Drug Product Portfolio
  42. 8.7.5 GlaxoSmithKline Plc Recent Developments
  43. 8.8 GeneOne Life Science, Inc.
  44. 8.8.1 GeneOne Life Science, Inc. Company Information
  45. 8.8.2 GeneOne Life Science, Inc. Business Overview
  46. 8.8.3 GeneOne Life Science, Inc. Herpes Zoste Drug Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 GeneOne Life Science, Inc. Herpes Zoste Drug Product Portfolio
  48. 8.8.5 GeneOne Life Science, Inc. Recent Developments
  49. 8.9 Foamix Pharmaceuticals Ltd.
  50. 8.9.1 Foamix Pharmaceuticals Ltd. Company Information
  51. 8.9.2 Foamix Pharmaceuticals Ltd. Business Overview
  52. 8.9.3 Foamix Pharmaceuticals Ltd. Herpes Zoste Drug Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Foamix Pharmaceuticals Ltd. Herpes Zoste Drug Product Portfolio
  54. 8.9.5 Foamix Pharmaceuticals Ltd. Recent Developments
  55. 8.10 Epiphany Biosciences, Inc.
  56. 8.10.1 Epiphany Biosciences, Inc. Company Information
  57. 8.10.2 Epiphany Biosciences, Inc. Business Overview
  58. 8.10.3 Epiphany Biosciences, Inc. Herpes Zoste Drug Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Epiphany Biosciences, Inc. Herpes Zoste Drug Product Portfolio
  60. 8.10.5 Epiphany Biosciences, Inc. Recent Developments
  61. 8.11 ContraVir Pharmaceuticals, Inc.
  62. 8.11.1 ContraVir Pharmaceuticals, Inc. Company Information
  63. 8.11.2 ContraVir Pharmaceuticals, Inc. Business Overview
  64. 8.11.3 ContraVir Pharmaceuticals, Inc. Herpes Zoste Drug Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 ContraVir Pharmaceuticals, Inc. Herpes Zoste Drug Product Portfolio
  66. 8.11.5 ContraVir Pharmaceuticals, Inc. Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Herpes Zoste Drug Value Chain Analysis
  2. 9.1.1 Herpes Zoste Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Herpes Zoste Drug Sales Mode & Process
  6. 9.2 Herpes Zoste Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Herpes Zoste Drug Distributors
  9. 9.2.3 Herpes Zoste Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst